228 related articles for article (PubMed ID: 21045188)
1. Safety of bevacizumab in patients with advanced cancer: a meta-analysis of randomized controlled trials.
Geiger-Gritsch S; Stollenwerk B; Miksad R; Guba B; Wild C; Siebert U
Oncologist; 2010; 15(11):1179-91. PubMed ID: 21045188
[TBL] [Abstract][Full Text] [Related]
2. Safety of bevacizumab in treating metastatic colorectal cancer: a systematic review and meta-analysis of all randomized clinical trials.
Dai F; Shu L; Bian Y; Wang Z; Yang Z; Chu W; Gao S
Clin Drug Investig; 2013 Nov; 33(11):779-88. PubMed ID: 23979925
[TBL] [Abstract][Full Text] [Related]
3. Risk of high-grade bleeding in patients with cancer treated with bevacizumab: a meta-analysis of randomized controlled trials.
Hang XF; Xu WS; Wang JX; Wang L; Xin HG; Zhang RQ; Ni W
Eur J Clin Pharmacol; 2011 Jun; 67(6):613-23. PubMed ID: 21243343
[TBL] [Abstract][Full Text] [Related]
4. Angiogenesis inhibitors for the treatment of ovarian cancer.
Gaitskell K; Martinek I; Bryant A; Kehoe S; Nicum S; Morrison J
Cochrane Database Syst Rev; 2011 Sep; (9):CD007930. PubMed ID: 21901715
[TBL] [Abstract][Full Text] [Related]
5. Bevacizumab in the treatment of advanced, non-squamous non-small cell lung cancer: an evidence-based approach.
Tassinari D; Sartori S; Papi M; Drudi F; Castellani C; Carloni F; Tombesi P; Lazzari-Agli L
Oncology; 2011; 80(5-6):350-8. PubMed ID: 21791945
[TBL] [Abstract][Full Text] [Related]
6. Antiangiogenic therapy for high-grade glioma.
Khasraw M; Ameratunga MS; Grant R; Wheeler H; Pavlakis N
Cochrane Database Syst Rev; 2014 Sep; (9):CD008218. PubMed ID: 25242542
[TBL] [Abstract][Full Text] [Related]
7. Effectiveness and safety of bevacizumab for unresectable non-small-cell lung cancer: a meta-analysis.
Yang K; Wang YJ; Chen XR; Chen HN
Clin Drug Investig; 2010; 30(4):229-41. PubMed ID: 20225906
[TBL] [Abstract][Full Text] [Related]
8. A meta-analysis of randomized controlled trials comparing chemotherapy plus bevacizumab with chemotherapy alone in metastatic colorectal cancer.
Cao Y; Tan A; Gao F; Liu L; Liao C; Mo Z
Int J Colorectal Dis; 2009 Jun; 24(6):677-85. PubMed ID: 19184059
[TBL] [Abstract][Full Text] [Related]
9. Risk of cardiac ischemia and arterial thromboembolic events with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis of randomized controlled trials.
Ranpura V; Hapani S; Chuang J; Wu S
Acta Oncol; 2010 Apr; 49(3):287-97. PubMed ID: 20156114
[TBL] [Abstract][Full Text] [Related]
10. Magnitude of risks and benefits of the addition of bevacizumab to chemotherapy for advanced breast cancer patients: Meta-regression analysis of randomized trials.
Cuppone F; Bria E; Vaccaro V; Puglisi F; Fabi A; Sperduti I; Carlini P; Milella M; Nisticò C; Russillo M; Papaldo P; Ferretti G; Aapro M; Giannarelli D; Cognetti F
J Exp Clin Cancer Res; 2011 May; 30(1):54. PubMed ID: 21569417
[TBL] [Abstract][Full Text] [Related]
11. Risk/benefit profile of bevacizumab in metastatic colon cancer: a systematic review and meta-analysis.
Galfrascoli E; Piva S; Cinquini M; Rossi A; La Verde N; Bramati A; Moretti A; Manazza A; Damia G; Torri V; Muserra G; Farina G; Garassino MC;
Dig Liver Dis; 2011 Apr; 43(4):286-94. PubMed ID: 21146479
[TBL] [Abstract][Full Text] [Related]
12. Safety and efficacy of first-line bevacizumab-based therapy in advanced non-squamous non-small-cell lung cancer (SAiL, MO19390): a phase 4 study.
Crinò L; Dansin E; Garrido P; Griesinger F; Laskin J; Pavlakis N; Stroiakovski D; Thatcher N; Tsai CM; Wu YL; Zhou C
Lancet Oncol; 2010 Aug; 11(8):733-40. PubMed ID: 20650686
[TBL] [Abstract][Full Text] [Related]
13. Bleeding events in bevacizumab-treated cancer patients who received full-dose anticoagulation and remained on study.
Leighl NB; Bennouna J; Yi J; Moore N; Hambleton J; Hurwitz H
Br J Cancer; 2011 Feb; 104(3):413-8. PubMed ID: 21245868
[TBL] [Abstract][Full Text] [Related]
14. Treatment-related mortality with bevacizumab in cancer patients: a meta-analysis.
Ranpura V; Hapani S; Wu S
JAMA; 2011 Feb; 305(5):487-94. PubMed ID: 21285426
[TBL] [Abstract][Full Text] [Related]
15. Bevacizumab increases risk for severe proteinuria in cancer patients.
Wu S; Kim C; Baer L; Zhu X
J Am Soc Nephrol; 2010 Aug; 21(8):1381-9. PubMed ID: 20538785
[TBL] [Abstract][Full Text] [Related]
16. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
17. Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis.
Nalluri SR; Chu D; Keresztes R; Zhu X; Wu S
JAMA; 2008 Nov; 300(19):2277-85. PubMed ID: 19017914
[TBL] [Abstract][Full Text] [Related]
18. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
[TBL] [Abstract][Full Text] [Related]
19. Bevacizumab versus ranibizumab for neovascular age-related macular degeneration: a meta-analysis of randomized controlled trials.
Chen G; Li W; Tzekov R; Jiang F; Mao S; Tong Y
Retina; 2015 Feb; 35(2):187-93. PubMed ID: 25105318
[TBL] [Abstract][Full Text] [Related]
20. Safety of bevacizumab in patients with metastatic breast cancer.
Hamilton EP; Blackwell KL
Oncology; 2011; 80(5-6):314-25. PubMed ID: 21778772
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
